Processing...
Clinical Trials for Prostate Cancer
Search
Search
There are 204 active trials for advanced/metastatic prostate cancer.
Click on a trial to see more information.
204 trials meet filter criteria.
Sort by:
HealthScout AI summary: Eligible patients are adults with metastatic solid tumors (ECOG 0-1, measurable disease, adequate organ function) who will receive MDX2001, a tetraspecific antibody that engages T cells via CD3/CD28 and targets TROP2 and c-MET on tumor cells. The trial excludes individuals with major cardiac disease, active brain metastases, uncontrolled infections, or unresolved toxicities.
ClinicalTrials.gov ID: NCT06239194
HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors expressing Nectin-4 who have progressed after or are ineligible for standard systemic therapy, excluding those with brain metastases or serious comorbidities. Patients receive IPH4502, a novel antibody-drug conjugate targeting Nectin-4 with an exatecan payload, administered as monotherapy.
ClinicalTrials.gov ID: NCT06781983
HealthScout AI summary: This trial enrolls adults with advanced solid tumors—including HNSCC, NSCLC, GI, GU, gynecologic, sarcoma, neuroendocrine, and NUT carcinoma—who have measurable disease and good performance status, to evaluate the intravenous BRD4 degrader MT-4561 administered weekly. MT-4561 is a novel agent targeting BRD4 for ubiquitin-mediated degradation and is being assessed primarily for safety and initial efficacy in this biomarker-unselected population.
ClinicalTrials.gov ID: NCT06943521
HealthScout AI summary: Enrolling adults with locally advanced or metastatic epithelial cancers (including multiple breast cancer subtypes, NSCLC, cervical, prostate, pancreatic, head and neck, endometrial, ovarian, gastric/GEJ, or urothelial carcinomas) who have progressed after ≥2 prior therapies and lack standard options, this study delivers IV DR-0202, a bispecific antibody targeting CLEC7A on myeloid cells and a tumor-associated antigen, aiming to activate myeloid-driven phagocytosis and antitumor immunity.
ClinicalTrials.gov ID: NCT06999187
HealthScout AI summary: This trial enrolls adults with advanced solid tumors harboring deleterious or suspected deleterious BRCA1/2 or other homologous recombination repair mutations—such as HER2-negative BRCA-mutant breast cancer, high-grade serous ovarian or fallopian tube cancer, metastatic castration-resistant prostate cancer, and pancreatic cancer—who have progressed on, are intolerant to, or are ineligible for standard therapies (including PARP inhibitors). Patients receive the investigational oral USP1 inhibitor XL309, which disrupts DNA repair, as monotherapy or in combination with olaparib.
ClinicalTrials.gov ID: NCT05932862
HealthScout AI summary: Adult patients with advanced solid tumors that are HLA-A*02:01 positive and harbor the p53 R175H mutation (confirmed by testing) receive CLSP-1025, a bispecific T-cell engager targeting the p53 R175H mutant peptide on tumor cells, as monotherapy. Prior p53 R175H-directed therapy, germline p53 mutations, and several comorbidities are exclusion criteria.
ClinicalTrials.gov ID: NCT06778863
HealthScout AI summary: This trial enrolls adults with advanced, nonresectable, or metastatic solid tumors—including HR+/HER2- breast cancer, platinum-resistant serous ovarian, endometrial, and other tumors with likely CDK2 dependency—who have progressed on standard therapies. Patients receive the investigational selective CDK2 inhibitor BG-68501 as monotherapy or in combination with fulvestrant, with HR+/HER2- breast cancer patients also eligible for a triple combination with fulvestrant and the selective CDK4 inhibitor BGB-43395.
ClinicalTrials.gov ID: NCT06257264
HealthScout AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors (excluding primary CNS tumors) who have progressed on or are intolerant to standard therapies, with preferential inclusion of BRCA2 loss-of-function cases. Patients receive ETX-19477, a novel reversible small molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG), given as monotherapy.
ClinicalTrials.gov ID: NCT06395519
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring homologous recombination deficiency (HRD), investigating the safety and activity of the investigational oral polymerase theta (Polθ) helicase inhibitor MOMA-313 as monotherapy or in combination with the PARP inhibitor olaparib. Eligible combination therapy patients include those with metastatic prostate, breast, or pancreatic cancer and must be PARP inhibitor naive.
ClinicalTrials.gov ID: NCT06545942
HealthScout AI summary: This trial enrolls adults with advanced solid tumors—including HER2-negative metastatic breast cancer, mCRPC, advanced pancreatic cancer, and platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer—who have progressed after standard therapy. Patients receive NUV-1511, an investigational drug-drug conjugate designed to selectively deliver a cytotoxic payload to tumor cells to enhance efficacy and limit systemic toxicity.
ClinicalTrials.gov ID: NCT06334432